The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2023 | Optimizing CAR-T therapy for patients with multiple myeloma in the real-world
In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses strategies to optimize the efficacy of CAR-T therapy for patients with multiple myeloma in the real-world setting. Dr Hansen also highlights the importance of further investigating the optimal sequencing of BCMA-targeted agents to improve patient outcome. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
